In a study of patients with cea-expressing medullary thyroid carcinoma, improved survival was found in the patients receiving the 131I–peptide after pre-targeting when those patients had a high tumour-marker (calcitonin) doubling time; patients not given radioimmunotherapy or lacking the increased calcitonin doubling time showed significantly poorer outcome 18. The gene discussed is CALCA; the disease is neoplasm.